USMLE Step 1 biochemistry & genetics questions

Thiamine (vitamin B1) is a cofactor for alpha-ketoglutarate dehydrogenase, pyruvate dehydrogenase, the branched-chain ketoacid dehydrogenase, and transketolase. In thiamine deficiency, reduced alpha-ketoglutarate dehydrogenase activity impairs the Krebs cycle and ATP production in neurons, which are highly dependent on oxidative metabolism, producing the oculomotor, gait, and memory disturbances of Wernicke encephalopathy as well as the peripheral polyneuropathy of dry beriberi. Areas with high metabolic demand and low thiamine reserve, such as the mammillary bodies and peripheral nerves, are most vulnerable. This is distinct from wet beriberi, which manifests as high-output cardiac failure.

• A. Methylmalonyl-CoA mutase requires vitamin B12, which causes a distinct syndrome with subacute combined degeneration.
• B. Pyruvate carboxylase requires biotin, not thiamine, and its deficiency causes a different pattern of lactic acidosis without neuropathy.
• C. Glucose-6-phosphate dehydrogenase deficiency causes hemolytic anemia, not a neurologic syndrome.
• E. Pyruvate dehydrogenase kinase activity is not the primary defect in thiamine deficiency; thiamine itself is a cofactor for pyruvate dehydrogenase.

This infant has a normal lactate-to-pyruvate ratio with elevated lactate, pyruvate, and alanine, a pattern consistent with pyruvate dehydrogenase complex (PDH) deficiency, which impairs conversion of pyruvate to acetyl-CoA and forces reliance on anaerobic glycolysis. Because PDH deficiency blocks carbohydrate-derived entry into the Krebs cycle, a ketogenic diet (high fat, low carbohydrate) bypasses the defect by supplying acetyl-CoA directly from fatty acid beta-oxidation and ketone body metabolism. A high-carbohydrate diet would worsen lactic acidosis by increasing pyruvate production that cannot be utilized. This contrasts with pyruvate carboxylase deficiency, which has a different biochemical signature and worse prognosis.

• A. Galactose restriction is used in galactosemia, which presents with hepatomegaly and cataracts, not lactic acidosis.
• B. A high-carbohydrate diet would increase glycolytic flux and worsen the lactic acidosis, since pyruvate cannot be efficiently converted to acetyl-CoA.
• C. Protein and branched-chain amino acid restriction is used in maple syrup urine disease, not PDH deficiency.
• D. Fructose restriction is used in hereditary fructose intolerance, which presents with hypoglycemia after fructose exposure, not this biochemical pattern.

Both vitamin B12 and folate deficiency cause megaloblastic anemia with elevated homocysteine, because both vitamins are required for the conversion of homocysteine to methionine (B12 as a cofactor for methionine synthase, folate as the methyl donor via methyltetrahydrofolate). However, only vitamin B12 is required for the conversion of methylmalonyl-CoA to succinyl-CoA by methylmalonyl-CoA mutase, so only B12 deficiency elevates methylmalonic acid. This patient's atrophic gastritis and subacute combined degeneration (dorsal column findings) point to B12 deficiency, and an elevated methylmalonic acid confirms it while remaining normal in isolated folate deficiency.

• B. Homocysteine is elevated in both B12 and folate deficiency, so it does not distinguish between them.
• C. Reticulocyte count is low in both conditions due to ineffective erythropoiesis and does not differentiate them.
• D. Serum iron is not characteristically altered in either B12 or folate deficiency.
• E. Macrocytosis with elevated MCV occurs in both B12 and folate deficiency.

Carcinoid tumors convert large amounts of dietary tryptophan into serotonin (5-hydroxytryptamine), which is then metabolized to 5-hydroxyindoleacetic acid and excreted in urine. This diverts tryptophan away from the kynurenine pathway, which normally supplies a minor endogenous source of niacin (vitamin B3) synthesis. The resulting niacin deficiency produces pellagra, classically described as the triad of dermatitis, diarrhea, and dementia, with the rash occurring in sun-exposed, symmetric distribution. This mechanism explains why carcinoid syndrome is a recognized secondary cause of pellagra even with adequate dietary niacin intake.

• A. Serotonin itself is not directly cytotoxic to keratinocytes; the skin findings result from niacin deficiency, not serotonin excess.
• B. Zinc deficiency causes a distinct perioral and acral dermatitis but does not explain the diarrhea-dementia triad or the tryptophan diversion mechanism.
• C. Carcinoid tumors consume tryptophan for serotonin synthesis, not thiamine.
• D. Carcinoid tumors do not characteristically cause bacterial overgrowth leading to B12 malabsorption, and B12 deficiency does not produce this particular rash pattern.

Zinc is a cofactor for many enzymes, including those involved in wound healing, collagen synthesis, and immune function. Zinc deficiency, which can occur with prolonged TPN if not adequately supplemented or with increased gastrointestinal losses from short bowel syndrome, classically presents with acrodermatitis enteropathica-like lesions (perioral, perianal, and acral erythematous crusted plaques), alopecia, and impaired wound healing. This patient's combination of periorificial dermatitis, hair loss, and poor wound healing on long-term TPN is the classic presentation of acquired zinc deficiency. Routine TPN formulations require careful trace element supplementation to prevent this complication.

• A. Vitamin K deficiency causes a bleeding diathesis from impaired clotting factor synthesis, not dermatitis or impaired wound healing.
• B. Copper deficiency causes anemia and neutropenia along with neurologic findings, not the described periorificial rash.
• C. Selenium deficiency causes cardiomyopathy (Keshan disease) and skeletal myopathy, not this dermatologic and wound-healing pattern.
• E. Essential fatty acid deficiency causes dry scaly skin and alopecia but does not typically cause this periorificial crusted rash or impaired wound healing as prominently.

Biotinidase is the enzyme responsible for cleaving biocytin and releasing free biotin from dietary and endogenous protein-bound sources, allowing biotin to be recycled and reused as a cofactor. Biotinidase deficiency is an autosomal recessive disorder that impairs this recycling, leading to a functional biotin deficiency despite potentially normal dietary intake, presenting with dermatitis, alopecia, and neurologic symptoms, detectable on newborn screening. This differs mechanistically from dietary biotin deficiency caused by excessive raw egg white consumption, in which avidin binds and sequesters biotin in the gut, preventing its absorption; both conditions converge on the same clinical picture because free biotin becomes unavailable as a cofactor for carboxylase enzymes.

• A. Acetyl-CoA carboxylase is another biotin-dependent carboxylase affected downstream, not responsible for releasing biotin from protein-bound sources.
• B. Pyruvate carboxylase is one of the biotin-dependent carboxylases whose activity is impaired as a downstream consequence of biotin deficiency, not the enzyme responsible for biotin recycling.
• C. Propionyl-CoA carboxylase is likewise a biotin-dependent enzyme affected downstream of biotin deficiency, not the cause of impaired biotin recycling.
• D. Holocarboxylase synthetase attaches biotin to apocarboxylase enzymes; its deficiency causes a similar clinical picture but is a distinct disorder affecting biotin utilization, not recycling from protein.

Classic galactosemia is caused by deficiency of galactose-1-phosphate uridyltransferase (GALT), which prevents conversion of galactose-1-phosphate to glucose-1-phosphate. Accumulation of galactose-1-phosphate damages the liver, kidney, and brain, while accumulation of galactitol (formed by aldose reductase) in the lens causes cataracts. Affected infants present after starting milk feeds (which contain lactose, broken down to glucose and galactose) with jaundice, hepatomegaly, hypoglycemia, and a urine positive for reducing substances (galactose) that is negative on glucose-specific test strips, as seen in this infant. Treatment requires complete elimination of galactose and lactose from the diet.

• A. Aldolase B deficiency causes hereditary fructose intolerance, which presents with hypoglycemia and liver dysfunction after fructose or sucrose ingestion, not with milk feeding or cataracts.
• B. Galactokinase deficiency causes a milder form of galactosemia with cataracts but without hepatomegaly, jaundice, or liver dysfunction, since galactose-1-phosphate does not accumulate.
• C. Glucose-6-phosphate dehydrogenase deficiency causes hemolytic anemia triggered by oxidative stress, not this hepatic and lenticular presentation.
• D. Fructokinase deficiency causes essential fructosuria, a benign asymptomatic condition.

This infant's presentation after introduction of fruit (fructose-containing food) with hypoglycemia, vomiting, and hepatomegaly is classic for hereditary fructose intolerance, caused by deficiency of aldolase B. Aldolase B deficiency leads to accumulation of fructose-1-phosphate, which traps phosphate and secondarily inhibits glycogenolysis and gluconeogenesis, producing severe hypoglycemia. The mainstay of management is strict dietary elimination of fructose, sucrose (which is hydrolyzed to fructose and glucose), and sorbitol. Genetic or enzymatic confirmation can follow, but the immediate priority once the diagnosis is clinically suspected is removing the offending sugars to prevent further hepatic and renal injury.

• A. Liver biopsy is invasive and unnecessary; diagnosis is typically made clinically and confirmed by genetic testing, not biopsy.
• B. Glucagon would not correct hypoglycemia because glycogenolysis is already inhibited by fructose-1-phosphate accumulation.
• D. Lactose restriction is irrelevant; lactose (glucose + galactose) is not the offending sugar in this disorder.
• E. There is no enzyme replacement therapy available for hereditary fructose intolerance.

This infant has von Gierke disease (glycogen storage disease type I), caused by deficiency of glucose-6-phosphatase, the enzyme required to dephosphorylate glucose-6-phosphate into free glucose that can exit hepatocytes. Because this final common step of both glycogenolysis and gluconeogenesis is blocked, glucose-6-phosphate accumulates and is shunted into glycolysis (producing lactate) and the pentose phosphate pathway (producing precursors for triglyceride and purine synthesis), explaining the lactic acidosis, hypertriglyceridemia, and hyperuricemia seen alongside severe fasting hypoglycemia. Hepatomegaly results from glycogen accumulation in the liver.

• A. This describes a fatty acid oxidation defect, which would not explain the markedly elevated lactate and uric acid seen here.
• C. Myophosphorylase deficiency affects skeletal muscle, not the liver, and does not cause fasting hypoglycemia.
• D. This describes debranching enzyme deficiency, which causes a milder phenotype (GSD type III) without lactic acidosis.
• E. Debranching enzyme deficiency (Cori disease) causes milder hypoglycemia and typically normal lactate levels.

This infant's presentation of severe hypotonia ("floppy baby"), macroglossia, massive cardiomegaly with hypertrophic cardiomyopathy, and hepatomegaly in the first year of life is classic for infantile-onset Pompe disease, caused by deficiency of lysosomal acid alpha-1,4-glucosidase (acid maltase). This enzyme normally degrades glycogen within lysosomes; its deficiency causes glycogen accumulation within lysosomes of cardiac and skeletal muscle, leading to cardiomegaly and profound hypotonia. Unlike other glycogen storage diseases, Pompe disease is a lysosomal storage disorder and classically affects the heart.

• A. Branching enzyme deficiency causes Andersen disease, a glycogen storage disease with cirrhosis, not the classic cardiac findings described.
• B. Hexosaminidase A deficiency causes Tay-Sachs disease, which presents with neurodegeneration and a cherry-red macula, not cardiomegaly or hepatomegaly.
• C. Alpha-galactosidase A deficiency causes Fabry disease, which presents with angiokeratomas and neuropathic pain, not infantile cardiomyopathy.
• D. Sphingomyelinase deficiency causes Niemann-Pick disease, presenting with hepatosplenomegaly and neurodegeneration but not characteristic massive cardiomegaly.

This patient's exercise intolerance, cramping, myoglobinuria, and second-wind phenomenon are classic for McArdle disease (glycogen storage disease type V), caused by deficiency of myophosphorylase, the muscle isoform of glycogen phosphorylase. Because muscle glycogenolysis is blocked, venous lactate fails to rise appropriately during the forearm ischemic exercise test, producing a flat lactate curve. Ammonia still rises normally because its production from the myoadenylate deaminase reaction (deamination of AMP) during exercise is independent of glycogenolysis, making a flat lactate curve with normal ammonia rise specific for a glycogenolysis defect like McArdle disease rather than a purine nucleotide cycle defect.

• B. A parallel normal rise in both would suggest no defect in glycogenolysis is present.
• C. A marked rise in both would be the expected normal response, not the abnormal finding in McArdle disease.
• D. A flat ammonia curve with normal lactate rise suggests myoadenylate deaminase deficiency, not McArdle disease.
• E. A decrease in lactate with exercise is not a recognized pattern and does not reflect this disorder's pathophysiology.

This asymptomatic infant with isolated fructose in the urine, normal growth, and no hepatic or metabolic derangement has essential fructosuria, caused by deficiency of fructokinase. Because fructokinase normally phosphorylates fructose to fructose-1-phosphate, its absence prevents fructose metabolism entirely, so fructose simply accumulates in blood and is excreted in urine without producing toxic metabolites. This is a benign, asymptomatic condition, in contrast to hereditary fructose intolerance, where aldolase B deficiency causes accumulation of toxic fructose-1-phosphate and severe symptoms after fructose ingestion.

• A. Fructose-1,6-bisphosphatase deficiency causes fasting hypoglycemia and lactic acidosis, not a benign asymptomatic presentation.
• B. Glycogen storage disease type I causes severe fasting hypoglycemia and hepatomegaly, not isolated asymptomatic fructosuria.
• C. Hereditary fructose intolerance causes vomiting, hypoglycemia, and hepatomegaly after fructose exposure, which are absent here.
• E. Galactosemia presents with jaundice, hepatomegaly, and a reducing sugar (galactose) that would be detected differently, not fructose.

This infant's progressive neurodegeneration, exaggerated startle response, cherry-red macula, and critically, the absence of hepatosplenomegaly point to Tay-Sachs disease, caused by hexosaminidase A deficiency. GM2 ganglioside accumulates in neurons, particularly affecting the central nervous system, which explains the neurologic findings and cherry-red spot without visceral organ involvement. This distinguishes Tay-Sachs from Niemann-Pick disease, which also causes a cherry-red macula and neurodegeneration but is distinguished by prominent hepatosplenomegaly due to sphingomyelin accumulation in the liver and spleen.

• B. Alpha-galactosidase A deficiency causes Fabry disease, which presents with angiokeratomas and neuropathic pain, not a cherry-red macula.
• C. Beta-glucocerebrosidase deficiency causes Gaucher disease, which presents with hepatosplenomegaly and bone pain, not a cherry-red macula.
• D. Arylsulfatase A deficiency causes metachromatic leukodystrophy, which presents with demyelination but not a cherry-red macula.
• E. Sphingomyelinase deficiency causes Niemann-Pick disease, which would present with hepatosplenomegaly, absent in this patient.

This patient's hepatosplenomegaly, cytopenias from hypersplenism, bone involvement (Erlenmeyer flask deformity), and bone marrow macrophages with a crinkled, tissue-paper cytoplasmic appearance (Gaucher cells) are classic for Gaucher disease, the most common lysosomal storage disease and especially prevalent among Ashkenazi Jews. It is caused by deficiency of glucocerebrosidase (beta-glucosidase), leading to accumulation of glucocerebroside within macrophages throughout the reticuloendothelial system, especially the spleen, liver, and bone marrow. Type 1 Gaucher disease, the most common form, does not involve the central nervous system, unlike types 2 and 3.

• A. Niemann-Pick disease causes hepatosplenomegaly but with foam cells on biopsy and typically prominent neurodegeneration, not Gaucher cells.
• B. Fabry disease causes angiokeratomas and neuropathy, not hepatosplenomegaly with crinkled-paper macrophages.
• C. Krabbe disease causes severe infantile neurodegeneration with globoid cells in the white matter, not hepatosplenomegaly.
• D. Metachromatic leukodystrophy causes demyelination with metachromatic granules, not hepatosplenomegaly or Gaucher cells.

I-cell disease (mucolipidosis II) results from a defect in N-acetylglucosamine-1-phosphotransferase, the enzyme that adds the mannose-6-phosphate tag to lysosomal enzymes in the Golgi apparatus. Without this tag, enzymes are not recognized by mannose-6-phosphate receptors and are not routed to lysosomes; instead they are default-secreted out of the cell. This leads to accumulation of undigested substrates within lysosomes, forming the characteristic dense inclusion bodies ('I-cells'), and markedly elevated lysosomal enzyme levels in the plasma and extracellular fluid. Clinically this produces a severe, Hurler-like phenotype with onset in infancy.

• A. Lysosome-endosome fusion is not the primary defect; the enzymes never reach the lysosome at all.
• C. The receptor itself is normal; the defect is in tagging the enzymes, not in receptor synthesis.
• D. Ubiquitin-proteasome degradation is unrelated to the trafficking defect seen in I-cell disease.
• E. Enzyme activity is normal when tested outside the cell but enzymes are misdirected, not overactive within the cell.

Phenylketonuria is caused by deficiency of phenylalanine hydroxylase, the enzyme that normally converts phenylalanine to tyrosine. Because this conversion pathway is blocked, tyrosine can no longer be synthesized endogenously from phenylalanine and becomes a conditionally essential amino acid that must be supplied in the diet. Reducing dietary phenylalanine alone would not correct the resulting tyrosine deficiency, which contributes to hypopigmentation (tyrosine is a precursor of melanin) and is needed for neurotransmitter and protein synthesis. The musty odor results from accumulated phenylalanine and its metabolites such as phenylacetate.

• A. Renal handling of these amino acids is not the mechanism driving the need for tyrosine supplementation.
• B. Tyrosine hydroxylase (which acts on tyrosine to form dopa) is a separate enzyme and is not the basis for supplementation.
• D. The enzyme defect is in phenylalanine hydroxylase itself or its cofactor regeneration, not in intestinal tyrosine absorption.
• E. Tyrosine supplementation does not restore phenylalanine hydroxylase activity, which remains deficient regardless of diet.

Maple syrup urine disease is caused by deficiency of branched-chain alpha-ketoacid dehydrogenase, a mitochondrial enzyme (structurally and mechanistically related to pyruvate dehydrogenase and requiring thiamine pyrophosphate as a cofactor) that catalyzes the oxidative decarboxylation of the alpha-ketoacids derived from leucine, isoleucine, and valine. Its deficiency causes accumulation of these branched-chain amino acids and their corresponding ketoacids, producing the characteristic sweet, maple syrup odor in urine and sweat, along with encephalopathy and poor feeding presenting within the first days to weeks of life. Elevated leucine is especially neurotoxic. Treatment involves dietary restriction of branched-chain amino acids and thiamine supplementation in some cases.

• A. Medium-chain acyl-CoA dehydrogenase deficiency impairs fatty acid oxidation and causes hypoketotic hypoglycemia, not elevated branched-chain amino acids.
• B. Methylmalonyl-CoA mutase deficiency causes methylmalonic acidemia with metabolic acidosis, not elevated branched-chain amino acids specifically.
• C. Propionyl-CoA carboxylase deficiency causes propionic acidemia, not isolated elevation of leucine, isoleucine, and valine.
• D. Isovaleryl-CoA dehydrogenase deficiency causes isovaleric acidemia, with a 'sweaty feet' odor, not elevated branched-chain amino acids as a group.

Alkaptonuria is caused by homogentisate oxidase deficiency, resulting in accumulation of homogentisic acid, which oxidizes and polymerizes on exposure to air, turning urine dark on standing. The accumulated pigment deposits in cartilage and connective tissue, producing ochronosis, bluish-black discoloration of ear cartilage and sclerae, along with degenerative arthropathy of the spine and large joints in adulthood. Unlike other aminoacidurias, alkaptonuria is a largely benign condition that does not cause intellectual disability, and the main long-term complications are arthritis and cartilage pigmentation.

• A. Hereditary tyrosinemia type I presents in infancy with liver failure and renal tubular dysfunction, not adult-onset dark urine and ochronosis.
• C. Maple syrup urine disease presents in neonates with encephalopathy and a sweet urine odor, not adult-onset joint disease.
• D. Homocystinuria presents with lens dislocation, thromboembolism, and marfanoid habitus, not dark urine or ochronosis.
• E. Phenylketonuria presents in infancy with intellectual disability and a musty odor, not dark urine or ochronosis in adulthood.

This patient has cystinuria, caused by a defective transporter for cystine and dibasic amino acids (ornithine, lysine, arginine) in the renal proximal tubule and intestine, leading to poor reabsorption and excessive urinary excretion of these amino acids. Cystine is poorly soluble in acidic urine and precipitates to form characteristic hexagonal crystals and recurrent stones. The mainstay of long-term prevention is high fluid intake to dilute urinary cystine and urinary alkalinization (for example with potassium citrate) to increase cystine solubility, since cystine solubility rises sharply at higher urinary pH.

• A. A high-protein diet increases cystine and dibasic amino acid excretion and would worsen stone formation.
• B. Thiazides reduce urinary calcium excretion and are used for calcium stones, not cystine stones.
• C. Calcium supplementation is not indicated and could worsen calcium-based stone risk; it does not address cystine solubility.
• E. Low-purine diet and allopurinol are used for uric acid stones, not cystine stones.

Cystathionine beta-synthase requires pyridoxal phosphate (vitamin B6) as a cofactor; many patients have residual enzyme activity that responds to high-dose B6 supplementation. Vitamin B12 and folate are added because they are cofactors/substrates for remethylation of homocysteine to methionine via methionine synthase, helping lower toxic homocysteine levels. This combined approach reduces thrombotic and ocular complications in B6-responsive homocystinuria. Dietary methionine restriction with cysteine supplementation is used concurrently.

• A. Biotin and carnitine are used in propionic acidemia and related organic acidemias, not homocystinuria.
• B. Ascorbic acid is not a cofactor for cystathionine beta-synthase and does not correct this defect.
• C. Riboflavin and niacin are cofactors for other dehydrogenases (e.g., FAD, NAD), unrelated to this pathway.
• E. Thiamine supports pyruvate dehydrogenase and branched-chain ketoacid dehydrogenase, not cystathionine synthase.

Ornithine transcarbamylase (OTC) deficiency is an X-linked urea cycle disorder in which the mitochondrial enzyme that normally combines carbamoyl phosphate with ornithine to form citrulline is deficient. Carbamoyl phosphate accumulates in the mitochondria and leaks into the cytosol, where it enters the de novo pyrimidine synthesis pathway via carbamoyl phosphate synthetase II, leading to orotic acid overproduction. This distinguishes OTC deficiency from other urea cycle defects, since citrulline levels are low (unlike citrullinemia or argininosuccinic aciduria, which show elevated citrulline or its byproducts).

• A. Ornithine does not accumulate in OTC deficiency; it is citrulline synthesis that is impaired, and ornithine is not elevated enough to inhibit this enzyme.
• B. Argininosuccinate lyase deficiency (argininosuccinic aciduria) causes elevated, not decreased, citrulline and does not match this infant's labs.
• C. There is no defect in mitochondrial citrulline transport in OTC deficiency; the defect is in citrulline synthesis itself.
• E. Ammonia does not directly stimulate carbamoyl phosphate synthetase II; the orotic aciduria results from substrate shunting, not enzyme activation.

DNA polymerase I is unique among the bacterial DNA polymerases in possessing 5' to 3' exonuclease activity, which it uses to excise RNA primers during lagging-strand synthesis, while its 5' to 3' polymerase activity fills the resulting gap with DNA. Its 3' to 5' exonuclease activity also provides proofreading. DNA polymerase III, in contrast, is the main processive replicative enzyme responsible for elongating the leading and lagging strands and has only 3' to 5' exonuclease (proofreading) activity, not 5' to 3' exonuclease activity. Loss of 5' to 3' exonuclease activity therefore specifically impairs primer removal, a function of polymerase I.

• A. DNA topoisomerase II (gyrase) relieves supercoiling ahead of the replication fork and is unrelated to primer excision.
• B. DNA ligase seals nicks between adjacent DNA fragments after gap filling; it does not excise RNA primers.
• C. DNA polymerase III lacks 5' to 3' exonuclease activity normally and is responsible for bulk strand elongation, not primer removal.
• D. DNA primase synthesizes RNA primers but has no role in removing them and has no exonuclease activity.

Xeroderma pigmentosum results from mutations in genes encoding proteins of the nucleotide excision repair pathway, which normally removes UV-induced bulky DNA lesions such as pyrimidine dimers. Deficient repair leads to accumulation of UV-induced mutations, causing extreme photosensitivity, early freckling, and a markedly increased risk of basal cell carcinoma, squamous cell carcinoma, and melanoma at a young age. The autosomal recessive inheritance and fibroblast defect in UV damage repair are classic for this diagnosis. Patients are advised to strictly avoid sun exposure.

• A. Lynch syndrome involves mismatch repair gene mutations causing colorectal and endometrial cancer, unrelated to UV sensitivity or nucleotide excision repair.
• B. Fanconi anemia involves defective DNA crosslink repair causing bone marrow failure and congenital anomalies, not primarily UV-related skin findings.
• D. Bloom syndrome involves a DNA helicase defect causing genomic instability, short stature, and photosensitive rash, but not this pattern of nucleotide excision repair failure.
• E. Ataxia-telangiectasia involves defective ATM kinase and double-strand break repair, presenting with cerebellar ataxia and telangiectasias, not primarily UV-induced skin cancer.

Lynch syndrome (hereditary nonpolyposis colorectal cancer) is caused by germline mutations in DNA mismatch repair genes (most commonly MLH1 and MSH2), which normally correct base-pair mismatches that escape DNA polymerase proofreading. Loss of mismatch repair function leads to accumulation of errors in short repetitive DNA sequences (microsatellites), a phenomenon called microsatellite instability, which drives tumorigenesis through mutation of genes regulating cell growth. This mechanism explains the early-onset, right-sided colorectal cancers and associated endometrial cancers seen in affected families, without antecedent diffuse polyposis.

• A. BRCA1 mutations impair homologous recombination repair and are associated with breast and ovarian cancer, not this colorectal and endometrial cancer pattern.
• B. MLH1 promoter hypermethylation causes sporadic microsatellite-unstable tumors, but this patient's strong family history indicates a germline mutation, not a sporadic epigenetic event.
• C. KRAS activation contributes to colorectal carcinogenesis in the adenoma-carcinoma sequence but does not explain the microsatellite instability or hereditary pattern described.
• E. APC inactivation characterizes the chromosomal instability pathway seen in familial adenomatous polyposis, which presents with numerous colonic polyps, not this family's pattern.

Ciprofloxacin and other fluoroquinolones inhibit bacterial DNA topoisomerase II (DNA gyrase), which introduces negative supercoils ahead of the replication fork, and topoisomerase IV, which separates interlinked daughter chromosomes after replication. This mechanism accounts for their antibacterial action, but fluoroquinolones also carry a well-recognized risk of tendinopathy and tendon rupture, particularly of the Achilles tendon, especially in older patients and those on concurrent corticosteroid therapy. The abrupt pain, palpable tendon defect, and positive Thompson test (absent plantarflexion on calf squeeze) are classic for Achilles tendon rupture.

• B. Trimethoprim-sulfamethoxazole inhibits folate synthesis enzymes and is associated with hyperkalemia and Stevens-Johnson syndrome, not tendinopathy.
• C. Doxycycline inhibits bacterial protein synthesis at the 30S ribosomal subunit and is associated with photosensitivity and tooth discoloration, not tendon rupture.
• D. Amoxicillin-clavulanate inhibits bacterial cell wall synthesis and is associated with hypersensitivity reactions, not tendon rupture.
• E. Nitrofurantoin generates reactive intermediates toxic to bacteria and is associated with pulmonary fibrosis and peripheral neuropathy, not tendon rupture.

Alpha-amanitin, the primary toxin in Amanita phalloides and related mushroom species, binds to and inhibits eukaryotic RNA polymerase II, which is responsible for transcribing messenger RNA. This blocks synthesis of mRNA needed for essential protein production, leading to cell death, with hepatocytes being especially vulnerable because of first-pass exposure through the portal circulation and high metabolic demand. The clinical course is classically biphasic: an initial gastrointestinal phase from direct mucosal toxicity, followed by a latent period, then fulminant hepatic failure with coagulopathy and encephalopathy days later. Treatment includes supportive care, and severe cases may require liver transplantation.

• A. DNA polymerase delta is involved in eukaryotic DNA replication, not transcription, and is not the target of alpha-amanitin.
• B. RNA polymerase I transcribes ribosomal RNA genes and is not significantly inhibited by alpha-amanitin at toxic doses relevant to this presentation.
• C. Telomerase maintains telomere length and is unrelated to the mechanism of alpha-amanitin-induced hepatotoxicity.
• D. Topoisomerase I relieves DNA supercoiling during replication and transcription but is not the target of alpha-amanitin toxicity.

Small interfering RNA (siRNA) drugs such as patisiran and inotersen-class agents work by base-pairing with complementary sequences in a target mRNA after being loaded into the RNA-induced silencing complex (RISC). The Argonaute protein within RISC then cleaves the bound mRNA, preventing its translation into protein. This mechanism allows sequence-specific knockdown of a disease-causing transcript, such as mutant transthyretin, without altering the genomic DNA. It differs from antisense oligonucleotides, which act by direct hybridization and recruitment of RNase H rather than RISC.

• A. This describes a mechanism like that of macrolide or oxazolidinone antibiotics acting on ribosomes.
• C. This describes a nucleoside reverse transcriptase inhibitor type mechanism, not RNA interference.
• D. This describes inhibition of mRNA capping enzymes, unrelated to siRNA.
• E. This describes an alkylating chemotherapeutic mechanism, not siRNA action.

The seventh codon changes from GAG (glutamate) to TAG, which is a premature stop codon. This causes translation to terminate early, producing a truncated beta-globin polypeptide that lacks the normal carboxy-terminal amino acids present in the wild-type protein. Nonsense mutations like this frequently lead to nonfunctional or rapidly degraded protein (often via nonsense-mediated decay of the mRNA) and are a recognized cause of beta-thalassemia. This differs from missense mutations, which substitute one amino acid without altering message length, and from frameshift mutations caused by insertions or deletions.

• A. The mutation occurs within the coding sequence and does affect the protein product.
• C. This describes a missense mutation, but the single-base change here created a stop codon, not an amino acid substitution.
• D. No nucleotide was inserted or deleted here, so the reading frame is unchanged aside from premature termination.
• E. A stop codon shortens rather than extends the protein.

The great majority of Down syndrome cases result from meiotic nondisjunction, most commonly failure of homologous chromosome 21 to separate during maternal meiosis I, leading to a gamete with two copies of chromosome 21 instead of one. Fertilization of this gamete produces a zygote with trisomy 21 (47 chromosomes total), confirmed on karyotype. The risk of nondisjunction increases significantly with maternal age, attributed to prolonged arrest of oocytes in meiosis I and age-related weakening of spindle fiber function. This is distinct from Robertsonian translocation Down syndrome, which is inherited and not related to maternal age.

• A. A deletion would reduce genetic material rather than cause trisomy.
• B. Dispermy would not selectively cause trisomy of only one chromosome pair.
• D. A translocation would produce an unbalanced karyotype with 46 chromosomes, not simple trisomy with 47 chromosomes, and is not the typical mechanism in this age group.
• E. Mosaicism would show a mixture of normal and trisomic cell lines, not uniform trisomy 21 in all cells as described.

The mother's karyotype of 45 chromosomes with a 14;21 Robertsonian translocation but a normal phenotype indicates she is a balanced carrier, since she has the normal diploid amount of genetic material despite having only 45 chromosomes total. During meiosis, she can produce a gamete carrying both the translocated chromosome and a normal chromosome 21, which upon fertilization with a normal gamete results in an unbalanced karyotype with effectively three copies of chromosome 21 material, causing Down syndrome. This familial form of Down syndrome is not related to maternal age and carries a significant recurrence risk in future pregnancies, unlike the sporadic nondisjunction form.

• A. The karyotype described is present in the infant generally, not described as mosaic or placenta-limited.
• C. The infant's karyotype shows a translocation chromosome, not three separate copies of chromosome 21, and the mother's carrier status is directly relevant.
• D. The mother already carries the same translocation, so it was inherited rather than arising de novo in the embryo.
• E. A ring chromosome is a distinct structural abnormality, not what is described here.

This patient's presentation of gynecomastia, small firm testes, tall stature, and elevated FSH and LH with low testosterone is classic for Klinefelter syndrome, caused by an extra X chromosome resulting in a 47,XXY karyotype. The additional X chromosome leads to seminiferous tubule dysgenesis and hyalinization, causing primary hypogonadism with impaired testosterone production and loss of negative feedback, which elevates gonadotropins. Buccal smear would show a Barr body, since one X chromosome is inactivated. This condition is the most common cause of male hypogonadism and infertility due to a chromosomal abnormality.

• B. This karyotype typically presents with tall stature and normal fertility, without gynecomastia or hypogonadism.
• C. This karyotype occurs in phenotypic females and is usually clinically silent, not causing male hypogonadism.
• D. This karyotype causes Turner syndrome, a female phenotype with webbed neck and streak gonads, not this presentation.
• E. This karyotype corresponds to a female phenotype and would not explain testicular findings.

This patient's short stature, webbed neck, widely spaced nipples, streak ovaries, and primary amenorrhea are classic features of Turner syndrome, caused by complete or partial loss of one X chromosome, typically a 45,X karyotype. The blood pressure discrepancy between the arms and legs along with a systolic murmur radiating to the back suggests coarctation of the aorta, a well-recognized cardiovascular association of Turner syndrome. Streak gonads result from accelerated oocyte atresia in utero due to the absence of a second X chromosome, leading to primary ovarian insufficiency and low estrogen with elevated gonadotropins. Turner syndrome is the most common cause of primary amenorrhea due to gonadal dysgenesis.

• A. This karyotype corresponds to a male phenotype, inconsistent with streak ovaries and this presentation.
• B. This karyotype occurs in phenotypic females but typically presents with a normal or mildly affected phenotype, not the classic features described.
• C. This karyotype occurs in phenotypic males and does not produce this female phenotype.
• E. This karyotype produces a male phenotype with gynecomastia and hypogonadism, not this presentation.

Prader-Willi syndrome results from loss of expression of paternally expressed, maternally imprinted genes in the 15q11-q13 region, most commonly from a deletion of the paternal chromosome 15. Because the maternal copy of this region is normally imprinted (silenced by methylation), its genes cannot compensate, so loss of the paternal allele eliminates all functional gene product. Angelman syndrome, in contrast, results from loss of the maternally expressed UBE3A gene, typically due to deletion of the maternal chromosome 15. This case specifies deletion of the paternally inherited chromosome, consistent with Prader-Willi syndrome.

• A. No translocation is described; the mechanism here is an interstitial deletion of the paternal chromosome 15.
• C. Uniparental disomy (two maternal copies) is an alternative cause of Prader-Willi syndrome but is not what is described here, since a deletion was identified.
• D. Loss of maternal UBE3A causes Angelman syndrome, which presents with seizures, ataxia, and inappropriate laughter, not this phenotype.
• E. Triplet repeat expansion describes diseases like Huntington disease or fragile X syndrome, not Prader-Willi syndrome.

Mitochondrial DNA is inherited exclusively from the mother because the sperm's mitochondria are largely excluded from the zygote, so an affected mother transmits the mutation to all of her children regardless of sex, while an affected father transmits it to none of his children. This pattern, combined with the clinical picture of progressive external ophthalmoplegia and exercise intolerance, which reflects impaired oxidative phosphorylation in high-energy tissues like muscle and eye, is classic for a mitochondrial DNA point mutation or deletion. Heteroplasmy also explains the variable severity often seen among affected relatives.

• A. Germline mosaicism would not produce the clean, exclusive maternal-to-all-offspring pattern described here.
• C. Autosomal dominant inheritance would show transmission from either affected parent to roughly half of offspring, not maternal-only transmission to all children.
• D. X-linked dominant disorders are transmitted by affected fathers to all daughters but no sons, which does not match this pattern.
• E. Imprinted autosomal genes still follow Mendelian transmission ratios modified by parent-of-origin silencing, not exclusive maternal transmission to all offspring.

In autosomal recessive inheritance, when both parents are heterozygous carriers (Aa x Aa), each pregnancy independently carries a 1 in 4 (25%) probability of producing a homozygous affected (aa) offspring, a 1 in 2 probability of an unaffected carrier (Aa), and a 1 in 4 probability of an unaffected homozygous normal (AA) offspring. Each conception is an independent event, so the outcome of a prior pregnancy does not change the probability for subsequent pregnancies; the gambler's fallacy does not apply to Mendelian segregation. Therefore the recurrence risk remains 25% for every pregnancy, regardless of the affected status of previous children.

• A. A 1 in 2 risk would apply if one parent were affected (aa) and the other a carrier (Aa), not two carrier parents.
• C. A 1 in 8 risk would require additional independent events, such as two separate recessive conditions each with 1 in 4 and 1 in 2 probabilities multiplied together.
• D. A 3 in 4 risk is the probability of an unaffected child (carrier or normal), not the probability of an affected child.
• E. A 1 in 3 risk is not a standard Mendelian ratio for a simple autosomal recessive cross.

Osteogenesis imperfecta is most commonly caused by autosomal dominant mutations in COL1A1 or COL1A2, the genes encoding the alpha chains of type I collagen, leading to either reduced quantity or abnormal structure of type I collagen, the major structural protein of bone, sclera, and teeth. This results in bone fragility with recurrent fractures from minimal trauma, blue-gray sclerae due to the translucency of the thin connective tissue overlying the choroid, and conductive or sensorineural hearing loss. The autosomal dominant inheritance pattern seen here, with an affected mother and affected child, is typical of the most common form, type I osteogenesis imperfecta.

• B. FBN1 mutations cause Marfan syndrome, which presents with tall stature, lens dislocation, and aortic root dilation rather than bone fragility and blue sclerae.
• C. COL3A1 mutations cause the vascular type of Ehlers-Danlos syndrome, which presents with arterial and organ rupture rather than this fracture and scleral pattern.
• D. Vitamin C deficiency, not a primary genetic prolyl hydroxylase defect, causes scurvy with impaired collagen hydroxylation; this is not the mechanism in osteogenesis imperfecta.
• E. LOX mutations impair collagen and elastin cross-linking and are associated with a rare form of Ehlers-Danlos syndrome, not the classic osteogenesis imperfecta presentation.

Ehlers-Danlos syndrome, most commonly the classic or hypermobile types, results from defective collagen synthesis or structure, often due to mutations in genes encoding type V collagen (COL5A1, COL5A2) or, in the hypermobile type, genes with less well-defined molecular causes, impairing normal collagen fibril assembly and cross-linking. This weakens the tensile strength of skin, joint capsules, and ligaments, producing the classic triad of skin hyperextensibility, joint hypermobility, and tissue fragility with poor wound healing and atrophic scarring. The absence of aortic or arterial complications in this vignette argues against the vascular type, which is caused by COL3A1 mutations affecting type III collagen.

• B. Fibrillin-1 mutations cause Marfan syndrome, which presents with skeletal overgrowth and aortic dilation rather than this skin and joint phenotype.
• C. Lysyl oxidase deficiency causes a rare form of Ehlers-Danlos syndrome but is a far less common cause than structural collagen gene defects and is not the best general answer here.
• D. Primary elastin gene mutations cause disorders such as cutis laxa, not the classic hypermobility and skin hyperextensibility seen in Ehlers-Danlos syndrome.
• E. LDL receptor mutations cause familial hypercholesterolemia, which is unrelated to connective tissue laxity and joint hypermobility.

Marfan syndrome is caused by autosomal dominant mutations in FBN1, encoding fibrillin-1, a glycoprotein essential for forming the extracellular matrix microfibrils that provide structural support to connective tissue and sequester transforming growth factor-beta in an inactive form; loss of normal fibrillin-1 leads to excessive TGF-beta signaling and connective tissue weakness. The classic triad of skeletal features (tall stature, arachnodactyly, pectus deformity), ocular findings (upward lens dislocation), and cardiovascular findings (aortic root dilation with risk of dissection) seen in this patient, combined with a family history of similar body habitus and aortic dissection, is diagnostic of Marfan syndrome.

• B. Multiple endocrine neoplasia type 2B causes a Marfanoid habitus with mucosal neuromas and medullary thyroid carcinoma, not lens dislocation or aortic root dilation.
• C. Vascular Ehlers-Danlos syndrome presents with thin, translucent skin and arterial or organ rupture rather than tall stature, arachnodactyly, and lens dislocation.
• D. Loeys-Dietz syndrome can cause aortic aneurysms and skeletal features but classically includes hypertelorism, bifid uvula, and arterial tortuosity rather than the upward lens dislocation seen here.
• E. Homocystinuria also causes lens dislocation and a Marfanoid habitus, but the lens typically dislocates downward and inward, and it is associated with intellectual disability and thromboembolism rather than isolated aortic root dilation.

Menkes disease is an X-linked recessive disorder caused by a mutation in ATP7A, which encodes a copper-transporting ATPase needed for copper absorption from the intestine and its delivery to copper-dependent enzymes such as lysyl oxidase. Loss of lysyl oxidase activity impairs collagen and elastin cross-linking, producing the connective tissue and vascular fragility seen in this disease, while low ceruloplasmin and low serum copper reflect defective copper transport. The twisted hair shaft (pili torti) and failure to thrive in a male infant are classic findings. Most affected children die by age 3 years from vascular complications or neurodegeneration.

• A. Marfan syndrome is due to a fibrillin-1 mutation and presents with tall stature, lens dislocation, and aortic root dilation, not abnormal hair or copper studies.
• B. Homocystinuria presents with lens dislocation, marfanoid habitus, and thrombosis, not abnormal hair shafts or low copper.
• C. Wilson disease causes copper accumulation (high tissue copper, low ceruloplasmin) from an ATP7B defect, not copper deficiency, and presents later with liver and basal ganglia disease.
• D. Ehlers-Danlos syndrome results from collagen synthesis or structure defects, not impaired copper transport, and does not cause pili torti or low ceruloplasmin.

Vitamin C (ascorbic acid) is a required cofactor for prolyl hydroxylase and lysyl hydroxylase, enzymes that hydroxylate proline and lysine residues on the procollagen alpha chains within the rough endoplasmic reticulum. Hydroxyproline and hydroxylysine are necessary for stabilizing the collagen triple helix through hydrogen bonding and for subsequent cross-linking. Vitamin C deficiency therefore produces unstable, poorly cross-linked collagen, manifesting as bleeding gums, perifollicular hemorrhages, corkscrew hairs, and poor wound healing, as seen in this patient's dehisced surgical wound. Treatment is ascorbic acid supplementation.

• A. Glycosylation of hydroxylysine occurs after hydroxylation and is not the vitamin C-dependent step itself.
• B. Lysyl oxidase-mediated cross-linking requires copper, not vitamin C; this step is deficient in Menkes disease, not scurvy.
• D. Triple helix formation depends on prior hydroxylation but is not itself the vitamin C-requiring enzymatic step.
• E. Propeptide cleavage occurs extracellularly during conversion of procollagen to tropocollagen and does not require vitamin C.

An unchanged Vmax with an increased Km on a Michaelis-Menten plot indicates competitive inhibition, in which the inhibitor competes with substrate for the active site. Because the inhibitor and substrate compete for the same binding site, raising substrate concentration can outcompete the inhibitor and restore the maximal reaction rate, so Vmax is unchanged while the apparent Km rises (lower apparent substrate affinity). On a Lineweaver-Burk plot, this appears as lines with the same y-intercept (1/Vmax) but different x-intercepts and slopes. This pattern is classically overcome by increasing substrate, unlike noncompetitive inhibition.

• A. Noncompetitive inhibition decreases Vmax while Km stays the same, since the inhibitor binds a separate site and cannot be outcompeted by substrate.
• B. Mixed inhibition changes both Vmax and Km, whereas this scenario shows Vmax unchanged, which is inconsistent with a mixed mechanism.
• C. Uncompetitive inhibition decreases both Vmax and Km because the inhibitor only binds the enzyme-substrate complex, which is not the pattern observed here.
• D. Irreversible covalent inhibition would permanently reduce the effective enzyme concentration and decrease Vmax regardless of substrate concentration.

ELISA is the standard initial screening test for detecting antibodies against a specific antigen in serum because it is rapid, highly sensitive, and suitable for large-scale testing. It uses an antigen or antibody bound to a plate, with a labeled secondary antibody producing a colorimetric signal proportional to the amount of target antibody present. A positive ELISA for HTLV-1 is typically confirmed with a Western blot, which detects antibodies against specific viral proteins separated by size. Southern and Northern blots detect DNA and RNA respectively, not antibodies, and are not used for serologic screening.

• A. Southern blot detects specific DNA sequences and is used for gene rearrangements or deletions, not for antibody detection.
• B. Western blot detects specific proteins (or antibodies against specific viral proteins) and is used as a confirmatory test after a positive ELISA, not as the initial screen.
• C. PCR amplifies DNA or RNA sequences to detect genetic material, not antibody levels, and is not the first-line screening test for HTLV-1 serology.
• E. Northern blot detects specific RNA transcripts to assess gene expression, not antibodies.

Polymerase chain reaction uses a thermostable DNA polymerase, classically Taq polymerase from Thermus aquaticus, to extend primers annealed to a denatured single-stranded DNA template and synthesize new complementary strands. Taq polymerase can withstand the high temperatures (around 95°C) used for strand denaturation in each cycle, unlike typical mammalian DNA polymerases. Each cycle of denaturation, primer annealing, and extension doubles the amount of target DNA, producing exponential amplification. Reverse transcriptase is used only in the initial step to convert RNA to cDNA when the starting material is RNA, as in this RNA virus workup.

• B. DNA ligase seals nicks between DNA fragments and is used in cloning or Okazaki fragment joining, not in PCR amplification.
• C. Helicase unwinds DNA during natural replication; in PCR, heat denaturation replaces this function rather than an enzyme.
• D. RNA polymerase II transcribes DNA into mRNA in eukaryotic cells and is not involved in PCR.
• E. Reverse transcriptase converts RNA into complementary DNA before PCR begins, but it does not perform the repeated amplification cycles.

I-cell disease (mucolipidosis II) results from a deficiency of N-acetylglucosamine-1-phosphotransferase, the Golgi enzyme that adds the mannose-6-phosphate tag to newly synthesized lysosomal enzymes. Without this tag, enzymes are not recognized by the mannose-6-phosphate receptor and fail to be sorted into lysosomes; instead they are secreted extracellularly, causing the characteristic high plasma lysosomal enzyme levels and absent intracellular digestion of substrates. This produces accumulation of undigested material in lysosomes (seen as inclusions), coarse facies, corneal clouding, and skeletal dysplasia, typically presenting in infancy with a severe, often fatal course. It is distinguished from other lysosomal storage diseases by this specific defect in post-translational tagging rather than deficiency of a single hydrolase.

• A. Impaired cholesterol transport out of late endosomes is the defect in Niemann-Pick disease type C, not I-cell disease.
• C. Lysosomal acidification defects would impair enzyme activity broadly but do not explain the extracellular secretion of unphosphorylated lysosomal enzymes characteristic of I-cell disease.
• D. Defective autophagosome-lysosome fusion is not the mechanism of I-cell disease and does not explain elevated plasma lysosomal enzymes.
• E. Signal peptide cleavage is a general step in protein synthesis for secretory and membrane proteins and is not specifically defective in I-cell disease.

This patient's presentation of stroke-like episodes, seizures, elevated lactate, and ragged red fibers on muscle biopsy is characteristic of MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), caused by mutations in mitochondrial DNA, most commonly in the MT-TL1 gene encoding a tRNA. Because mitochondrial DNA is maternally inherited and each cell contains many mitochondria, a mutation can exist in varying proportions alongside wild-type mitochondrial DNA, a phenomenon called heteroplasmy. The proportion of mutant mitochondrial DNA varies randomly during oocyte development and cell division, so tissues and family members can have different mutant loads and thus different disease severity and organ involvement. This explains why clinical presentation can differ substantially even among maternally related individuals carrying the same underlying mutation.

• A. Mitochondrial DNA is not subject to genomic imprinting; imprinting affects specific nuclear genes based on parent of origin.
• B. X-linked inactivation applies to genes on the X chromosome, not to mitochondrial DNA, which is inherited maternally and cytoplasmic.
• D. MELAS is a mitochondrial DNA disorder with maternal inheritance, not an autosomal dominant nuclear gene disorder with incomplete penetrance.
• E. MELAS is caused by point mutations in mitochondrial DNA, not trinucleotide repeat expansions, so anticipation does not apply.

In chronic starvation, insulin secretion is low and intracellular phosphate, potassium, and magnesium stores become depleted even though serum levels may be normal. Reintroducing carbohydrates causes a surge in insulin, which drives glucose and phosphate into cells to support glycolysis (formation of glucose-6-phosphate, fructose-6-phosphate, and ATP). This rapid intracellular shift depletes serum phosphate, producing the hypophosphatemia, hypokalemia, and hypomagnesemia characteristic of refeeding syndrome. Severe hypophosphatemia impairs ATP generation and can cause cardiac arrhythmias, rhabdomyolysis, and respiratory failure. Prevention requires slow caloric reintroduction and electrolyte monitoring in malnourished patients.

• A. Diarrhea is not described in this vignette and is not the principal mechanism of refeeding hypophosphatemia.
• C. Glucagon is suppressed, not stimulated, by carbohydrate refeeding, and it does not primarily cause renal phosphate wasting in this setting.
• D. Enteral formulas do not contain enough calcium to cause clinically significant phosphate binding in the gut this quickly.
• E. Parathyroid hormone changes are not the primary driver; the main mechanism is intracellular shift from insulin, and PTH may actually rise in response to falling phosphate and calcium.

This child has kwashiorkor, protein malnutrition with relatively preserved total caloric intake. Inadequate dietary protein limits hepatic synthesis of albumin and other plasma proteins, lowering plasma oncotic pressure and allowing fluid to shift into the interstitium, producing the characteristic edema, along with a protuberant abdomen (ascites and hepatomegaly from fatty liver), skin and hair changes, and growth faltering. This distinguishes kwashiorkor from marasmus, in which both calories and protein are deficient, leading to severe muscle wasting and loss of subcutaneous fat without edema. Fatty liver occurs in kwashiorkor because reduced apolipoprotein synthesis impairs export of hepatic triglycerides as VLDL.

• A. Filariasis causes localized lymphedema, not the generalized edema pattern with hypoalbuminemia described here.
• B. There is no evidence of a systemic inflammatory or infectious process causing capillary leak in this vignette.
• D. There is no proteinuria history given, and nephrotic syndrome would not explain the hair, skin, and abdominal findings together.
• E. There is no history or exam finding (such as jugular venous distension or gallop rhythm) suggesting cardiac dysfunction.

Primary carnitine deficiency impairs the carnitine shuttle, which transports long-chain fatty acyl groups across the inner mitochondrial membrane as acylcarnitines (via carnitine palmitoyltransferase I and II) for beta-oxidation. Without this transport, long-chain fatty acids cannot be oxidized to generate ATP and ketone bodies, so during fasting or illness the body cannot use fat for fuel, leading to hypoketotic hypoglycemia, lethargy, and lipid accumulation in muscle and liver (not heart failure or hypertrophic cardiomyopathy in this vignette, though that can occur). Low free and total carnitine with a normal acylcarnitine profile reflects the primary carnitine transporter defect rather than an enzyme block further down the pathway. Treatment is oral L-carnitine supplementation.

• A. Defective ketogenesis at this step would still show a normal or elevated carnitine profile and accumulated acetyl-CoA, not low total carnitine with normal acylcarnitines.
• B. Pyruvate dehydrogenase deficiency causes lactic acidosis and neurologic findings, not primarily hypoketotic hypoglycemia with low carnitine levels.
• D. MCAD deficiency would show an abnormal acylcarnitine profile with elevated medium-chain species, not a normal profile with low total carnitine.
• E. Glucose-6-phosphatase deficiency (von Gierke disease) causes fasting hypoglycemia with lactic acidosis and hepatomegaly, not a carnitine abnormality.

Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an autosomal recessive disorder of mitochondrial fatty acid beta-oxidation that prevents oxidation of medium-chain fatty acids (6-12 carbons). During prolonged fasting or illness, when the body should shift to fatty acid oxidation and ketogenesis, deficient infants instead develop hypoketotic hypoglycemia, lethargy, and can progress to seizures, coma, or sudden death. The diagnostic clue is elevated octanoylcarnitine (C8) on acylcarnitine profile and medium-chain dicarboxylic aciduria. Management includes avoiding prolonged fasting and providing frequent carbohydrate-rich feeds; MCAD deficiency is part of routine newborn screening in the US.

• B. Acetyl-CoA carboxylase is involved in fatty acid synthesis, not oxidation, and its deficiency would not produce this acylcarnitine pattern.
• C. HMG-CoA lyase deficiency impairs the final step of ketogenesis and causes hypoketotic hypoglycemia with a different organic acid pattern (3-hydroxy-3-methylglutaric aciduria), not elevated C8-carnitine.
• D. LCHAD deficiency affects long-chain fatty acid oxidation and classically causes elevated long-chain hydroxyacylcarnitines, not C8.
• E. CPT I deficiency impairs long-chain fatty acid entry into mitochondria and would show an abnormal long-chain, not medium-chain (C8), acylcarnitine pattern.

Lesch-Nyhan syndrome is an X-linked recessive disorder caused by deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), an enzyme of the purine salvage pathway that normally recycles hypoxanthine and guanine back into nucleotides using PRPP. Loss of this salvage pathway shunts purine bases toward degradation into uric acid, producing hyperuricemia, gout, and orange urate crystals ("orange sand") in the diapers of affected infants. The buildup of PRPP (not consumed in salvage) also drives de novo purine synthesis, worsening hyperuricemia, while the neurologic effects produce characteristic self-mutilating behavior, dystonia, and intellectual disability. Treatment with allopurinol or febuxostat lowers uric acid but does not address the neurologic manifestations.

• A. Adenine phosphoribosyltransferase deficiency causes 2,8-dihydroxyadenine kidney stones, not the gout and self-mutilation seen in Lesch-Nyhan syndrome.
• B. Xanthine oxidase deficiency causes xanthinuria with low, not high, uric acid levels and does not cause this neurobehavioral syndrome.
• C. PRPP synthetase overactivity (gain-of-function), not deficiency, is associated with a similar but distinct hyperuricemia and neurologic syndrome; this is not the classic cause of Lesch-Nyhan.
• E. Adenosine deaminase deficiency causes severe combined immunodeficiency from toxic accumulation of deoxyadenosine, not this self-mutilation and urate crystal phenotype.